Enhanced antivirulent for antibiotic-resistant bacteria
AssigneeLiveLeaf, Inc.
InventorsALEXANDER L. HUANG, GIN WU
Life of this patent
Estimating the term…
Abstract
The teachings provided herein generally relate to enhanced antivirulents that inactivate antibiotic-resistant bacteria without killing them, and the antivirulents are safe for oral administration. More particularly, the systems taught herein include methods of treating a subject having an antibiotic-resistant bacterial infection, comprising administering an effective amount of a antivirulents to a subject having an antibiotic-resistant bacterial infection.
Claims12
A method of inhibiting the virulence of a pathogen in the gastrointestinal tract of a subject, comprising:
- identifying a pathogen in the gastrointestinal system of a subject;
- orally administering an effective amount of a composition to the subject, the composition comprising a combination of:
- an aqueous extract of pomegranate rind to an aqueous extract of green tea leaves in an aqueous concentration of about 600 ppm to about 900 ppm;
- and,
- hydrogen peroxide in an aqueous concentration of about 30 ppm to about 1000 ppm;
- wherein, the combination inhibits the virulence of the pathogen in the subject by inactivating virulence factors in the pathogen without involving antibiotic resistance mechanisms.
A method of treating a subject having an antibiotic-resistant bacterial infection, comprising:
- identifying an antibiotic-resistant bacterial infection in the subject;
- orally administering an effective amount of a composition to the subject having the antibiotic-resistant bacterial infection, the composition comprising a combination of:
- an aqueous extract of pomegranate rind to an aqueous extract of green tea leaves in an aqueous concentration of about 600 ppm to about 900 ppm;
- and,
- hydrogen peroxide in an aqueous concentration of about 30 ppm to about 1000 ppm;
- wherein, the administering inhibits the virulence of the antibiotic resistant bacteria in the subject by inactivating virulence factors in the antibiotic-resistant pathogen without involving antibiotic resistance mechanisms.
The method of claim 16, wherein the antibiotic-resistant bacteria is a methicillin resistant Staphylococcus aureus (MRSA).
The method of claim 16, wherein the antibiotic-resistant bacteria is an antibiotic-resistant Klebsiella pneumonia.
The method of claim 16, wherein the antibiotic-resistant bacteria is an antibiotic-resistant bacteria selected from the group consisting of Escherichia coli, Salmonella enterica serotype typhimurium, Staphylococcus aureus, a methicillin resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa, Listeria monocytogenes, Pasteurella multocida, Proteus vulgaris, Klebsiella pneumonia, Bacillus cereus, and Bordetella bronchiseptica.
The method of claim 16, wherein the antibiotic-resistant bacteria is an antibiotic-resistant Salmonella enterica serotype typhimurium.
The method of claim 16, wherein the antibiotic-resistant bacteria is an antibiotic-resistant Pseudomonas aeruginosa.
Dependencies are inferred from the claim text.